drugset / Trial / NCT05260437
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
Non-randomizedSequentialOpen-labelPrevention
Summary
Prevention of COVID-19 caused by SARS-CoV-2.
Timeline
- Start
- 2022-03-24
- Primary completion
- 2023-03-07
- Completion
- 2023-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CV2CoV | Messenger RNA (mRNA) | 2 ug | Intramuscular |
| Subject | CV2CoV | Messenger RNA (mRNA) | 4 ug | Intramuscular |
| Subject | CV2CoV | Messenger RNA (mRNA) | 8 ug | Intramuscular |
| Subject | CV2CoV | Messenger RNA (mRNA) | 12 ug | Intramuscular |
| Subject | CV2CoV | Messenger RNA (mRNA) | 16 ug | Intramuscular |
| Subject | CV2CoV | Messenger RNA (mRNA) | 20 ug | Intramuscular |